Alembic Pharmaceuticals Ltd (ALEM.NS)
17 Jan 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|66||2016||Executive Chairman of the Board, Chief Executive Officer|
|54||2014||Chief Financial Officer, Director - Finance, Executive Director|
|2014||Associate Vice President-Finance, Company Secretary and Compliance Officer|
|38||2016||Managing Director, Executive Director|
|2016||Managing Director, Director|
- BRIEF-Alembic Pharmaceuticals Says U.S. FDA Grants Orphan-Drug Designation To Rhizen Pharmaceuticals
- BRIEF-Alembic Pharma Gets U.S. FDA Nod For Generic Drug to Treat Overactive Bladder
- BRIEF-India's Alembic Pharma Sept-qtr consol PAT rises
- BRIEF-Alembic Pharma buys generic drug developer Orit Laboratories
- BRIEF-Alembic Pharmaceuticals gets EU GMP certificate for audit conducted at Panelav